Advertisement
"Redington has been retained to expand Urigen's outreach and visibility inthe US financial community, with particular emphasis on transactional brokers,wealth managers and high net worth individuals," said Martin Shmagin, UrigenCFO. "As Urigen's clinical programs develop, this outreach program will beexpanded to include sector growth investment funds."
Advertisement
Among the companies Redington has helped with investment communitysponsorship are Amgen, Calgene, Elan, Celgene, Keryx, Medarex and Crucell.
"Urigen is in the process of building out its drug portfolio and movingforward on the strength of clinical achievements," noted Thomas Redington,President of Redington, Inc. "The company went public quietly last summerthrough a reverse merger process and remains unknown to a large part of thefinancial community. This engagement presents the opportunity to developimportant new interest among a number of different financial audiences."
With specific expertise in the biopharma industry, Redington will assistUrigen in developing and managing investor relations programs that willinclude market road shows and investor meetings in principal financial centersacross America.
About Urigen
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated tothe development and commercialization of therapeutic products for urologicaldisorders. Urigen's product development programs target significant unmetmedical needs and major market opportunities in urology. URG101 targetspainful bladder syndrome/interstitial cystitis, which affects approximately10.5 million men and women in North America. URG201 targets malehypogonadism, which has been estimated to effect 13 million men in the UntiedStates. Urigen's URG301 project targets urethritis and acute urgency inpatients diagnosed with an overactive bladder. For further information,please visit Urigen's website at http://www.urigen.com.
About Redington
Redington, Inc. is a financial communications and investor relations firmwith a specialty practice for emerging life sciences companies. It provides afull range of communications and corporate services, including messagedevelopment, presentation structure and content, market road shows, editorialproducts including executive speeches, news releases, investor literature andannual reports, media relations, institutional and analyst introductions, andbroker relationship management. For more information please visitwww.redingtoninc.com.Contact: Martin E. Shmagin Chief Financial Officer 650-259-0239 www.urigen.com Thomas Redington 203/222-7399 212/926-1733 www.redingtoninc.com
SOURCE Urigen Pharmaceuticals, Inc.
